Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in minority patients with relapsing multiple sclerosis
NCT04377555Phase 4Completed
- Sponsor
- Genentech
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 4 trial of ocrelizumab in multiple sclerosis (MS), sponsored by Genentech. Started Jul 2020; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04377555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377555.